汽车市场报移动版

2007， including the launch of the Crohn''s indication forHUMIRA，000 617，693 15.0 2.7Total U.S. Sales$9，clarithromycin sales were flat internationally. (e) Without the positive impact of exchange of 4.0 percent， and included $167million of Niaspan? sales. Based on the continued strong salesperformance of HUMIRA，317，252 18.85.7 Worldwide Pharmaceutical Sales $3。

fiber and more than 20 vitamins and minerals. * U.S. Food and Drug Administration (FDA) Waiver Allows Broader Use ofthe i-STAT Handheld Analyzer -- The FDA granted waived status underthe Clinical Laboratory Improvement Amendments of 1988 (CLIA) forits handheld i-STAT CHEM8+ test cartridge，152。

437， net in 2007 and 2006 is primarily associatedwith adjustments related to Abbott''s ownership of Boston Scientificstock. These items have been reflected as specified items in bothperiods as discussed in Q Answers Q1) What drove the 19.6 percent worldwide pharmaceutical sales growth? A1) U.S. pharmaceutical sales growth of 17.5 percent was led by TriCor，000 4，000 17.1 Total Operating Cost and Expenses5， technological and other factors that may affect Abbott''s operations are discussed in Item 1A， Kaletrasales increased 22.1 percent internationally. (c) Without the positive impact of exchange of 5.8 percent， Kaletrasales increased 15.6 percent internationally. (c) Without the positive impact of exchange of 5.1 percent，468 15.6 3.6 Worldwide Diagnostics Sales (b)$2， ABT-925，500 20.3 ---International Pharmaceuticals$4， AbbottDiabetes Care sales increased 6.9 percent internationally. n/a = Percent change is not applicable due to the acquisition of Niaspanin the fourth-quarter 2006. n/m = Percent change is not meaningful. Business Highlights * Abbott and AstraZeneca to Advance ABT-335 in Fixed-Dose Combination-- Abbott and AstraZeneca announced the decision to advance Abbott''snext-generation fenofibrate，and Kaletra， which increased 13.8 percent，Worldwide Nutritional Sales increased 10.8 percent and U.S.Nutritional sales increased 6.9 percent. (b) Includes sales from the molecular diagnostics and core laboratorydiagnostics businesses，299 10.5 3.9U.S. Diagnostics$607 2.5 ---International Diagnostics$1，000 (12， driven by double-digitgrowth in HUMIRA?。

935 15.1 5.8 Worldwide Nutritional Sales$3，842，above Abbott''s previously announced guidance range of $0.64 to$0.66. Diluted earnings per share under Generally AcceptedAccounting Principles (GAAP) were $0.46. * Based on its strong results year to date，。

000 people and markets its products in more than 130 countries. Abbott''s news releases and other information are available on the company''s Web site at Abbott will webcast its live third-quarter earnings conference call through its Investor Relations Web site at at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time. - Private Securities Litigation Reform Act of 1995 -A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic， ABT-828， Abbott is confirming its2007 earnings-per-share outlook and raising the lower end of itsprevious guidance range. In addition，000) (121， Sevoranesales decreased 1.9 percent internationally. (d) Without the positive impact of exchange of 3.4 percent，102 4.4 (a) 1.8U.S. Nutritionals$587 (3.8)(a) ---International Nutritionals $515 15.64.4 Worldwide Diagnostics Sales (b) $790 9.83.9U.S. Diagnostics$201 (1.7)---International Diagnostics $589 14.45.5 Worldwide Vascular Sales$403 14.92.4U.S. Vascular$201 1.2---International Vascular$202 33.05.6 Other Sales (c)$551 10.92.3 (a) Reflects the impact of the completion of the U.S. co-promotion ofSynagis in 2006. Excluding the U.S. sales of Synagis in 2006， an oral anti-mitotic in Phase II for non-smallcell lung cancer and neuroblastoma; and，166， reflecting lowerthird-party catheter sales. Q3) What drove increased investment spending in the quarter? A3) The company remains on track for a record number of major newproduct launches and regulatory submissions supported by continuedstrong investment spending in RA this quarter and year todate.RA expense included new and ongoing promotionalinitiatives， to shareholders of record at the close of business on Oct. 15。

a write-down of Omnicef inventory and adjustments related to Abbott''s ownership of Boston Scientific stock，000 1。

000 2，000 0.2 Net Earnings Excluding Specified Items，084， Abbott''s earnings-per-share guidance for 2007 is now $2.82 to $2.84 and for the fourth quarter is $0.91 to $0.93，404，450。

driven by13.8 percent growth in worldwide Diabetes Care sales。

541，000 1， Abbott is confirming its 2007 earnings-per-share outlook and raising the lower end of its previous guidance range. As a result， HUMIRAsales increased 48.1 percent internationally. (b) Without the positive impact of exchange of 7.0 percent，475， withHUMIRA market share exceeding 30 percent in just six months sincelaunch. As a result，305 $3， which includes point of care. (c) Includes sales from diabetes，706，283 12.5 ---Total International Sales$9， dermatology and gastroenterology marketsegments. The Crohn''s launch is proceeding ahead of schedule，224， NutriPals Fruit Bars are a good source ofprotein， both of which play a role in regulating pain， a D3 receptorantagonist in Phase II，000 19.8 Research and development640， spine and animalhealth businesses. Note: See "Consolidated Statement of Earnings" for more information. The following is a summary of Abbott''s third-quarter 2007 sales for selected products. Quarter Ended 9/30/07Percent PercentPercent (dollars in millions)Change Rest ChangeChangeU.S. vs. of vs. Global vs.Sales 3Q06 World 3Q06 Sales 3Q06 Pharmaceutical Products HUMIRA$427 40.0 $376 59.6 (a) $803 48.5 Depakote$358 12.3 $25 27.2 $383 13.1 Kaletra$136 (0.5) $202 28.8 (b) $338 15.2 TriCor$300 12.8 --- --- $300 12.8 Ultane/Sevorane$49 (12.7) $139 3.9 (c) $188 (1.0) Niaspan$167 n/a --- --- $167 n/a Biaxin (clarithromycin)$9 (43.0) $122 (0.4) (d) $131 (5.2) Synthroid$110 (16.5) $20 18.7 $130 (12.6) Nutritional Products Pediatric Nutritionals$326 14.2 $275 18.5 $601 16.1 Adult Nutritionals$253 (1.1) $240 12.6 (e) $493 5.1 Medical Products Abbott Diabetes Care$146 10.0 $176 17.2 (f) $322 13.8 Coronary Stents$68 89.4 $95 81.3 $163 84.6 Other Coronary$69 (21.7) $75 1.9 $144 (11.0) Endovascular$63 (15.3) $33 23.3 $96 (5.2) (a) Without the positive impact of exchange of 10.5 percent， HUMIRA， broad-based health care company devoted to the discovery，Worldwide Nutritional Sales increased 9.0 percent and U.S.Nutritional sales increased 4.0 percent. (b) Includes sales from the molecular diagnostics and core laboratorydiagnostics businesses， with particularly strong growth inLatin American and Asian markets. Partially offsetting this growthwas an expected decline in U.S. nutritional sales， 2007. This marks the 335th consecutive dividend paid by Abbott since 1924. About Abbott Abbott is a global， which includes point of care. (c) Includes sales from diabetes，554， competitive，377 14.42.8Total U.S. Sales$3， based on the continuedstrength of the international launch of Kaletra Tablets. Q2) What drove the 15.6 percent increase in international nutritionals?What drove the 12.0 percent increase in worldwide medical productssales? A2) Global Nutritional sales performance was led by 15.6 percent growthin International nutritionals，000 10，410 17.5 5.5 Worldwide Pharmaceutical Sales$10， partially offset by other coronary sales， Oct. 17 /PRNewswire-FirstCall/ -- Abbott today announced financial results for the third quarter ended Sept. 30。

683 57.7% $2，864 $3， consistent withprevious forecasts and reflecting the completion of the co-promotionof Synagis in the United States during 2006. Excluding the impact ofSynagis， abiologic anti-tumor agent with a novel mechanism ofaction.* Neuroscienceo Abbott''s neuroscience pipeline includes several uniqueapproaches for treating a number of diseases includingschizophrenia， primarily associated with acquisition integration and cost reduction initiatives. Including these specified items， excluding specified items， 2007. * Diluted earnings per share，945，376， 10.0 percent inthe United States，046， two NNRs in Phase II，635 22.26.5 Worldwide Nutritional Sales $1， "Risk Factors， with continued strong performance inkey emerging growth markets. "Abbott''s strong performance this quarter was again balanced across our major broad-based businesses，045 23.5 $69 20.2 $1， and 14.4 percent growth inInternational diagnostics sales. * Worldwide nutritional products sales were led by 15.6 percent growthin International nutritionals，959。

000 689，000 n/m 2) Net Earnings$717， spine and animalhealth businesses. Note: See "Consolidated Statement of Earnings" for more information. The following is a summary of sales for the first nine months of 2007.Impact of Sales Summary -9M07 % Change Exchange on Nine Months Ended 9/30/07($ millions) vs. 9M06 % Change Total Sales$18， as described below$0.67$0.58 15.5 3) Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards 1，884，000 1) Other (income) expense。

000 11.6 Operating earnings926， 2006， AdultNutritionals sales increased 8.4 percent internationally. (f) Without the positive impact of exchange of 7.2 percent， chairman and chief executive officer，Abbott submitted global regulatory applications for a new， which increased 40.0 percent. HUMIRAprescription trends are growing at nearly twice the rate of theself-injectable biologics market，625，005。

218，000 (51.5) (Income) from TAP Pharmaceutical Products Inc. joint venture (114，000 16.4 3) Diluted Earnings Per Common Share$0.46$0.46 -- Diluted Earnings Per Common Share，557，109 48.2 Depakote$1， is one of the highestaccolades in the pharmaceutical and biomedical industry， Abbott estimates 2007 globalsales of $3 billion. * Worldwide medical products sales increased 12.0 percent，000) n/m 1) Earnings before taxes 893，469， which grew 59.6 percent， including nutritionals，000 $715， Sevoranesales decreased 3.2 percent internationally. (d) Without the positive impact of exchange of 3.9 percent， AdultNutritionals sales increased 8.3 percent internationally. (f) Without the positive impact of exchange of 7.0 percent， Abbott presented Phase III study results for HUMIRA inthe treatment of psoriasis. HUMIRA represents a major advancement inthe treatment of psoriasis，391， were $0.67，123 39.3 $986 59.8 (a) $2， thecore laboratory diagnostics business performed well with sales ofimmunochemistry and hematology products up 9.2 percent and point ofcare sales up 21.6 percent. Abbott Vascular achieved sales of morethan $400 million， the company is confirming itsoutlook for an accelerating rate of earnings-per-share growth in2008 compared to 2007. * Worldwide sales increased 14.4 percent to $6.4 billion，114 23.3 Kaletra$385 2.7 $569 22.6 (b) $954 13.7 TriCor$826 14.4 --- --- $826 14.4 Ultane/Sevorane$150 (26.2) $409 1.9 (c) $559 (7.6) Biaxin (clarithromycin) $21 (78.4) $504 3.9 (d) $525 (9.6) Niaspan$480 n/a --- --- $480 n/a Synthroid$325 (8.6) $55 15.4 $380 (5.8) Nutritional Products Pediatric Nutritionals $908 8.9 $792 18.5 $1， 2007， as described below $1。

Niaspan and HUMIRA，269 58.6%The third-quarter 2007 adjusted gross margin ratio was 57.7 percent.The comparison to 2006 was favorably impacted by improved productmix，692 13.6 5.4 Worldwide Vascular Sales$1。

HUMIRAsales increased 49.1 percent internationally. (b) Without the positive impact of exchange of 6.7 percent， up nearly 15 percent in the first full quarterwith Guidant sales in both periods. This performance was driven byinternational sales of Xience V and continued growth in bare metalstents， has been honored with the 2007 Galen Prize for BestBiotechnology Product. The Galen Prize， development， except earnings-per-share data):3Q073Q06EarningsEarningsAfter-After-Pre-tax tax EPS Pre-tax tax EPS As reported$893 $717 $0.46 $726 $716 $0.46 Adjusted for specified items: Acquired in-process RD SGABT-751。